Log in or Sign up for Free to view tailored content for your specialty!
Oncology News
HCC inhibitor receives FDA orphan drug designation
Casi Pharmaceuticals has received an orphan drug designation from the FDA for ENMD-2076 to treat hepatocellular carcinoma, according to a press release.
NCAN polymorphism associated with HCC, alcoholic liver disease
The neurocan rs2228603 polymorphism is associated with alcoholic liver disease and hepatocellular carcinoma, according to study results.
Log in or Sign up for Free to view tailored content for your specialty!
High frequency of Treg cells associated with HCC
Patients with hepatocellular carcinoma had a larger number of regulatory T cells compared with controls, indicating an association between T-cell frequency and pathogenesis of cancer, according to study results.
Everolimus failed to improve OS in advanced HCC
Patients with advanced hepatocellular carcinoma who were intolerant to or experienced disease progression on sorafenib did not derive an OS benefit from everolimus, according to results of the phase 3 EVOLVE-1 trial.
HKLC scoring system improved therapy options, survival outcomes in patients with HCC
The Hong Kong Liver Cancer scoring system was effective when recommending treatment for patients with hepatocellular carcinoma compared with the Barcelona Clinic Liver Cancer system, according to data from a recent study.
Nucleos(t)ide analog therapy reduced HCC risk in patients with chronic HBV
Patients with chronic hepatitis B virus who underwent nucleos(t)ide analog therapy had a lower risk for hepatocellular carcinoma compared with untreated patients, according to new research data.
Biomarkers predicted OS after living-donor liver transplantation in patients with HCC
Pre-transplant neutrophil-lymphocyte ratio and C-reactive protein levels were effective biomarkers when detecting overall survival and disease-free survival rates among patients who underwent living-donor liver transplantation for hepatocellular carcinoma, according to recent data.
BCAA decreased risk for HCC, death among patients with cirrhosis
Patients with cirrhosis who received branched-chain amino acid supplementation had a decreased risk for hepatocellular carcinoma and mortality, according to data from a recent study.
Radioembolization induced hypertrophy, may be option for patients with liver malignancy
Radioembolization induced significantly less contralateral hypertrophy than portal vein embolization, but still may be a modality option for induction in patients with liver tumors, according to recent research data.
Cyramza fails to meet primary endpoint in hepatocellular carcinoma
Results from the phase 3 REACH trial have found that ramucirumab did not meet its primary endpoint of OS when used as a second-line treatment for hepatocellular carcinoma, manufacturer Eli Lilly said in a press release.
-
Headline News
Q&A: 1 in 5 COVID-19 deaths due to strain of hospital overcrowding
September 25, 20244 min read -
Headline News
Impact of Dobbs ‘immediate and profound’ on OB/GYN residents in Wisconsin
September 25, 20246 min read -
Headline News
FDA approves second Niemann-Pick disease type C treatment
September 25, 20241 min read
-
Headline News
Q&A: 1 in 5 COVID-19 deaths due to strain of hospital overcrowding
September 25, 20244 min read -
Headline News
Impact of Dobbs ‘immediate and profound’ on OB/GYN residents in Wisconsin
September 25, 20246 min read -
Headline News
FDA approves second Niemann-Pick disease type C treatment
September 25, 20241 min read